Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Denise N Keller und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Services, London Health Sciences Centre, 339 Windermere Road, London, ON N6A 5A5, Canada. Hauptthemen laut MEDLINE: Tamoxifen, Cytochrome P-450 CYP2D6, Cytochrome P-450 CYP2D6 Inhibitors, Breast Neoplasms. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research Project, Canadian Institutes of Health Research Team Grant: Personalized Health, Wolfe Medical Research Chair in Pharmacogenomics.
Abstract (Originalsprache)
Objectives
Tamoxifen is a prodrug that undergoes cytochrome P450(CYP)-mediated bioactivation to its active metabolite endoxifen, primarily due to CYP2D6. We aimed to investigate the clinical impact of CYP2D6 phenotype on the conversion of tamoxifen to endoxifen as well as the interplay of genetic variation and drug interactions.
Methods
Samples were analyzed from a cohort of 932 breast cancer patients on tamoxifen therapy. CYP2D6 phenotype, tamoxifen, endoxifen, 4-hydroxytamoxifen, and N-desmethyl tamoxifen plasma concentrations and antidepressant CYP2D6 inhibitor use were analyzed. Key findings There was a significant effect of CYP2D6 phenotype and CYP2D6 inhibitor use on endoxifen concentrations (pinteraction < 0.05). CYP2D6 inhibition was predictive of patients who attained plasma endoxifen concentrations below the 16 nM and 9 nM threshold. CYP2D6 poor metabolizers and CYP2D6 normal or intermediate metabolizers on strong CYP2D6 inhibitors had the largest proportion of patients below an endoxifen threshold of 16 or 9 nM.
Conclusions
Patients on tamoxifen should avoid strong CYP2D6 inhibitors as their endoxifen concentrations are similar to CYP2D6 poor metabolizers. The utility of endoxifen concentrations and which threshold to consider in clinical practice remains unclear. Ultimately, the clinical impact of mild or moderate CYP2D6 inhibitors on CYP2D6 normal or intermediate metabolizer depends on the endoxifen threshold applied.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Services, London Health Sciences Centre, 339 Windermere Road, London, ON N6A 5A5, Canada.
- Department of Medicine, Western University, 1151 Richmond St, London, ON N6A 5C1, Canada.
- Department of Physiology and Pharmacology, Western University, 1151 Richmond St, London, ON N6A 5C1, Canada.
ORCID-Profile: Denise N Keller, Richard B Kim
Förderung
- Canadian Institutes of Health Research Project
- Canadian Institutes of Health Research Team Grant: Personalized Health
- Wolfe Medical Research Chair in Pharmacogenomics
Zitieren
APA
Keller, D. N., Medwid, S. J., Legan, R. M., Schwarz, U. I., & Kim, R. B. (2026). Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf132
Vancouver
Keller DN, Medwid SJ, Legan RM, Schwarz UI, Kim RB. Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf132
BibTeX
@article{Keller2026,
author = {Keller, Denise N and Medwid, Samantha J and Legan, Robin M and Schwarz, Ute I and Kim, Richard B},
title = {Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf132}
}
EUVIMED